New here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
For most of medical history, vitiligo had no fix. Doctors could sometimes slow the spreading white patches, but regrowing lost skin color was mostly out of reach.
Pfizer is testing a daily pill to change that. Its drug, ritlecitinib, calms the immune attack on pigment cells and lets color return to skin. In July 2026, two large Phase 3 trials showed it worked.
Why it matters
Roughly 1 in 100 people have vitiligo. A pill that regrows lost skin color could become the first systemic treatment for the disease.
Questions about this story
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Timeline
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Sign up to save your score and track a streak across stories.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
Pfizer is the U.S. drugmaker developing oral ritlecitinib as a systemic treatment for vitiligo.
Incyte makes Opzelura, the first drug the FDA cleared to restore pigment in vitiligo.
The Food and Drug Administration decides whether Pfizer's pill can be sold for vitiligo in the United States.
Timeline
July 2022 July 2026
-
Phase 3 trials succeed
Latest Clinical DataPfizer said both TRANQUILLO Phase 3 trials met their co-primary goals at 52 weeks across 2,174 patients. The company plans to seek approval globally.
-
Extension study adds phototherapy
Clinical DataPhase 2b extension results in the Journal of the American Academy of Dermatology showed pairing the pill with narrow-band UVB light improved repigmentation, with response rising over 48 weeks.
-
Reports say Pfizer's pill regrows skin color
Clinical DataNews outlets reported that oral ritlecitinib restored pigment in vitiligo patients during Pfizer's trial. The mid-stage results built the case to advance to Phase 3.
-
Ritlecitinib approved for a hair-loss disease
RegulatoryThe FDA approved ritlecitinib as LITFULO for severe alopecia areata. The approval set the pill's safety profile and cleared the way to test it in vitiligo.
-
FDA approves first repigmentation drug
RegulatoryThe FDA approved Opzelura, a ruxolitinib cream from Incyte. It was the first treatment proven to restore skin color in nonsegmental vitiligo, but practical only for limited areas.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Opzelura wins first vitiligo approval (2022)
The FDA approved Incyte's ruxolitinib cream after the TRuE-V trials, which enrolled about 600 patients. It was the first drug ever proven to restore pigment in vitiligo, not just cover or slow it.
Patients gained their first proven repigmentation option, though the cream suits limited areas like the face.
The approval set the trial endpoints, the facial and total-body scoring indexes, that Pfizer's oral drug now has to beat.
It is the benchmark Pfizer must clear. A pill would extend treatment to people whose disease is too widespread for a cream.
FDA orders boxed warnings on JAK pills (2021)
After a safety study of tofacitinib called ORAL Surveillance, the FDA required boxed warnings across oral JAK inhibitors. The warnings flag serious infections, blood clots, cancer, and heart events.
The warnings narrowed how broadly doctors could prescribe oral JAK drugs.
Every new oral JAK inhibitor, including ritlecitinib, carries the class warning.
It shapes how freely a vitiligo pill can be used. Regulators weigh serious risks against a disease that is not life-threatening.
Biologics remake psoriasis treatment (2000s)
Systemic immune drugs like etanercept and adalimumab moved psoriasis care beyond creams and light boxes. They cleared skin for many patients and built a multibillion-dollar market.
Patients with severe disease gained durable clearance for the first time.
Systemic therapy became the standard for widespread skin disease, reshaping treatment and drug economics.
It shows the path Pfizer hopes to repeat: a systemic option can reset how a common skin disease is treated and paid for.
